A Phase II, randomised, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated starting dose of a new formulation of ropinirole in Parkinson's Disease patients not receiving other dopaminergic therapies
Parkinson Disease
Phase 2
A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
June 2014